These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38845072)
21. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Parekh M; Fendrick AM; Ladabaum U Aliment Pharmacol Ther; 2008 Apr; 27(8):697-712. PubMed ID: 18248653 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis. Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657 [TBL] [Abstract][Full Text] [Related]
24. The economic evaluation of screening for colorectal cancer: Case of Iran. Barouni M; Ghaderi H; Shahmoradi MK Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368 [TBL] [Abstract][Full Text] [Related]
25. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Sonnenberg A; Delcò F; Inadomi JM Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584 [TBL] [Abstract][Full Text] [Related]
27. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366 [TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population. Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455 [TBL] [Abstract][Full Text] [Related]
30. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. van Hees F; Saini SD; Lansdorp-Vogelaar I; Vijan S; Meester RG; de Koning HJ; Zauber AG; van Ballegooijen M Gastroenterology; 2015 Nov; 149(6):1425-37. PubMed ID: 26253304 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of single colonoscopy versus single fecal test for colorectal cancer diagnosis and treatment. Ishibashi F; Suzuki S; Kobayashi K; Tanaka R; Kawakami T; Mochida K; Nagai M; Ishibashi Y; Morishita T J Gastroenterol Hepatol; 2024 Jul; 39(7):1328-1335. PubMed ID: 38348570 [TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. O'Leary BA; Olynyk JK; Neville AM; Platell CF J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241 [TBL] [Abstract][Full Text] [Related]
33. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100 [No Abstract] [Full Text] [Related]
34. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Knudsen AB; Hur C; Gazelle GS; Schrag D; McFarland EG; Kuntz KM Ann Intern Med; 2012 Nov; 157(9):611-20. PubMed ID: 23128861 [TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China. Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W Front Public Health; 2022; 10():952378. PubMed ID: 36033786 [TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of screening strategies for colorectal cancer. Barzi A; Lenz HJ; Quinn DI; Sadeghi S Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness Analysis of Colorectal Cancer Screening Strategies Using Active Learning and Monte Carlo Simulation. Fouladi A; Asadi A; Sherer EA; Madadi M Med Decis Making; 2024 Jul; 44(5):554-571. PubMed ID: 38907706 [TBL] [Abstract][Full Text] [Related]
39. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514 [TBL] [Abstract][Full Text] [Related]